Champions Oncology Inc : Losses of 1  cents announced for first quarter

Champions Oncology

13/09/2021 22:48

13 September 202109:48 p.m. ​All figures in US dollars.
The loss announced by Champions Oncology Inc in the first
quarter  were lower than the Refinitiv mean estimate  of
profits.  The company reported losses of  -1 cents per share, 2
cents lower than the same quarter last year when the company
reported EPS of 1 cents.  Profits of  1 cents per share were
forecast by the single analyst providing an estimate for the
quarter.      The company reported revenue of $11.25 million,
which is higher than the estimated $10.98 million. 
RECOMMENDATIONS 
* The consensus recommendation for the company is "Buy".      
* The average consensus recommendation for the biotechnology &
medical research peer group is also "Buy".  
 
FORECAST CHANGES
* Two analysts are currently providing Refinitiv with
estimates. 
* In the last week there have been no earnings estimate
revisions by analysts covering the company. There was a loss of
one estimate. 
 
YEAR OVER YEAR
* The company reported an increase in revenue to $11.25 million
from $9.55 million in the same quarter last year.
​
* Previous quarterly performance (using earnings preferred
measure)
 QUARTER ENDING    ESTIMATE          ACTUAL      BEAT, MET,
                                                 MISSED
 Apr. 30 2021      0.00​             -0.04       Missed
 Jan. 31 2021      0.01              0.05        Beat
 Oct. 31 2020      0.00              0.00        Met​
 Jul. 31 2020      0.02              0.01        Missed
 This summary was machine generated from Refinitiv data September
13 at 09:48 p.m